Dose: 250 mcg/m²
Single Dose: 250 (250)
Frequency: As recommended.
Route: IV Infusion
Instructions:

.

Sargramostim is contraindicated in conditions like Myeloblastic leukemia,Hypersensitivity.

The severe or irreversible adverse effects of Sargramostim, which give rise to further complications include Allergic reactions, Weight gain, Dizziness, Chest pain.The signs and symptoms that are produced after the acute overdosage of Sargramostim include Nausea, Shortness of breadth, Fever, Rashes.The symptomatic adverse reactions produced by Sargramostim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Bone pain, Muscle aching, Loss of appetite.

Sargramostim is primarily indicated in conditions like Acute myeloid leukemia, Bone marrow transplantation, and can also be given in adjunctive therapy as an alternative drug of choice in Infections, Neutropenia.

Sargramostim is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementIndacaterolConcomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose.not recommended These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Store in a well closed container, Below -15°C. Do not Freeze.

Sargramostim should be used in pregnancy if clearly needed. Cautions should be taken if patient is taking other chemotherapeutic drugs.